Zhendong Liu

Zhendong Liu

Auto-generated profile, based on publicly available information

Zhendong Liu

People’s Hospital of Zhengzhou University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2022 in Future Oncology
Verified
Journal Article
Closed access
YZYongjie Zhu
Yongjie Zhu
ZLZhendong Liu
Zhendong Liu
DLDongbo Lv
Dongbo Lv
XCXingbo Cheng
Xingbo Cheng
JWJialin Wang
Jialin Wang
延高延正 高
延正 高
Aim: PYGL has been reported to have carcinogenic effects in a variety of tumors. This study is the first to reveal the relationship between PYGL and the prognosis of glioma. Materials & methods: An...

9 September 2025 in Neurological Research
Verified
Journal Article
Closed access
ZZZongye Zhang
Zongye Zhang
ZSZhi Sha
Zhi Sha
HLHan Liu
Han Liu
YCYusheng Chen
Yusheng Chen
ZLZhendong Liu
Zhendong Liu
延高延正 高
延正 高
Immunotherapy holds significant yet underexplored potential for low-grade glioma (LGG) treatment. We therefore interrogated the role of Fanconi Anemia Complementation Group C (FANCC) as a novel immune checkpoint regulator given its spatial correlation with tumor microenvironments and clinical associations with immunosuppressive markers. FANCC is implicated in various tumor progressions; its role in LGG remains unexplored. This study comprehensively investigates FANCC's clinical significance, prognostic value, and molecular mechanisms driving LGG malignancy to identify novel therapeutic targets. FANCC overexpression in malignant single-cell subclusters correlated with advanced grade/recurrence. It independently predicted poor prognosis (KM log-rank p < 0.001; multivariate Cox HR = 2.1, p < 0.001). Spatial mapping revealed colocalization with immunosuppressive niches, supported by strong correlations with CD4+ T cells (r = 0.68) and M2 macrophages (r = 0.72), while inversely linking to M1 markers (r = -0.42). Immune checkpoints (PD-1/CTLA-4) showed significant co-expression (r > 0.4). GSEA implicated FANCC in DNA replication and base excision repair (FDR < 0.05), suggesting genomic instability drives progression. As the first-reported oncogenic driver in LGG, FANCC synergistically fuels progression via immune microenvironment reprogramming and DNA repair dysregulation, establishing its potential as a diagnostic/prognostic biomarker and therapeutic target.